Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Closes
- Oct 8, 2027 (in 404 days)
Similar opportunities open now
- Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Sep 2027
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 2027
- Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2027
- Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 2028
- Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Sep 2028
Classification and identifiers
- Solicitation number
- PAR-25-248
- Assistance listing (CFDA)
- 93.393
Amount
Amount not published by the funder
Who can apply
State government agencies, Public colleges and universities, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of ca...